MedDataX Logo

Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

NCT ID: NCT04952766

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

196 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-26

Study Completion Date

2022-02-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons, in comparison to healthy subject. Secondary objectives are to evaluate the humoral response in the nasal mucosa, and the capacity of antibodies to neutralize emerging variants of concerns and to prevent COVID-19.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The serious, even fatal, forms of COVID-19 preferentially affect elderly and fragile subjects. Among these populations at risk, people who are immunocompromised (either by a disease and / or its treatment) have a theoretical risk of responding less well to a preventive vaccination.

The main objective of this study aims to compare the vaccine response of immunocompromised people with healthy subjects (non-immunocompromised), i.e. to assess the serum humoral response (titre and neutralizing capacity of the antibodies induced) following vaccination with ComirnatyTM (i.e. BNT162b2, an anti-SARS-CoV-2 vaccine from Pfizer BioNTech) in immunocompromised persons in comparison to healthy subjects (non-immunocompromised).

Secondary objectives are as follows:

* To evaluate the antibody response in the nasal mucosa (titre and neutralizing capacity of the antibodies induced, collected by means of a nasopharyngeal swab) following vaccination with ComirnatyTM in immunocompromised people as compared to healthy subjects (vaccinated either with two doses of ComirnatyTM or, in a subgroup, with one dose of Astra Zeneca's VaxzeriaTM followed by one dose of ComirnatyTM).
* Evaluate the serum and mucosal antibody response (titre and neutralizing capacity of the antibodies induced) against emerging strains of SARS-CoV-2 (so-called Alpha, Beta, Gamma, Delta strains).
* Evaluate the post-vaccination clinical protection against the risk of COVID-19 infection (incident cases after vaccination).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant Myeloma Cancer Hematologic Malignancy Multiple Sclerosis Hypergammaglobulinemia Malignant Tumor Hiv Diabetes Type 2

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

SARS-CoV-2 BNT162b2 vaccine antibody neutralization mucosa immunocompromised healthy subject

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All participants wil have at each of the 4 visits (for patients starting at month 1) or 5 visits (for patients starting at month 0):

1. a venipuncture sample of 2 dry tubes of 7 mL (less than 30 mL in total) to make up 3 aliquots and
2. a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

immunocompromised and healthy subjects

Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.

Biological samples :

* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests
* Nasopharyngeal samples (not mandatory)

Associated data :

* Demographic data
* Description of clinical manifestations related to vaccination
* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning
* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)

Group Type OTHER

Biological samples

Intervention Type BIOLOGICAL

Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.

Biological samples :

* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests
* Nasopharyngeal samples (not mandatory)

Associated data :

* Demographic data
* Description of clinical manifestations related to vaccination
* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning
* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological samples

Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.

Biological samples :

* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests
* Nasopharyngeal samples (not mandatory)

Associated data :

* Demographic data
* Description of clinical manifestations related to vaccination
* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning
* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult volunteers to be vaccinated with the ComirnatyTM vaccine and to participate in the study, belonging to one of the following groups:

* Group of immunocompromised (15 participants per immunosuppression subgroup):

* Kidney transplant
* Extracorporeal dialysis
* Solid cancer under chemotherapy and / or radiotherapy
* Myeloma under chemotherapy
* Hematologic malignancies under chemotherapy
* Diseases treated with anti CD20 (or patients not treated at the time of the vaccine but who will be immediately after)
* Multiple sclerosis under anti CD20 (or patients not treated at the time of the vaccine but who will be immediately after)
* Common variable immune deficiency or other causes of severe hypogammaglobulinemia requiring chronic treatment with polyvalent immunoglobulin
* Malignant tumor under anti-PD1 or anti-PDL1
* People living with HIV
* Complicated type 2 diabetes (with micro and / or macroangiopathy)
* Group of non-immunocompromised subjects (controls, n = 75)

* 60 people vaccinated with the ComirnatyTM
* 15 people vaccinated with Astra Zeneca's VaxzevriaTM for the first dose

Exclusion Criteria

* Minors
* Pregnant or breastfeeding women
* Persons under tutorship or curatorship
* Protected adults
* Person under legal protection
* Person not affiliated to a social security scheme
* People with a contraindication to receiving the ComirnatyTM vaccine
* People who have already been vaccinated against SARS-CoV-2

Note: a history of COVID-19 (\> at 3 months) is not a contraindication to vaccination and is therefore not a criterion for non-inclusion in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Régional d'Orléans

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aymeric SEVE, Dr

Role: PRINCIPAL_INVESTIGATOR

CHU Orléans

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Orléans

Orléans, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouenan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Creach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020 Sep 2;12(559):eabc3103. doi: 10.1126/scitranslmed.abc3103. Epub 2020 Aug 17.

Reference Type BACKGROUND
PMID: 32817357 (View on PubMed)

Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Prot M, Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon E, Schortgen F, Yahyaoui L, Gonzalez M, De Seze J, Pere H, Veyer D, Seve A, Simon-Loriere E, Fafi-Kremer S, Stefic K, Mouquet H, Hocqueloux L, van der Werf S, Prazuck T, Schwartz O. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.

Reference Type BACKGROUND
PMID: 33772244 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHRO-2021-04

Identifier Type: -

Identifier Source: org_study_id